Libor Staněk
Impact in
-
- Diabetes Treatment and Management
- Diabetes Management and Research
- Pharmacology top 5%
- Pharmacology and Obesity Treatment
Papers in
- Oncology 3
-
- Diabetes Treatment and Management 2
- Co-authors
- Pavel Dundr (3 shared papers)Ján Laco (2 shared papers)Kristýna Němejcová (1 shared paper)Sarah L. Kenny (1 shared paper)W. Glenn McCluggage (1 shared paper)Michal Zikan (1 shared paper)Petr Škapa (1 shared paper)Petra Kleiblová (1 shared paper)
- Journals
- The Lancet (2 papers)The American Journal of Surgical Pathology (1 paper)Journal of Perinatal Medicine (1 paper)Medical Science Monitor (1 paper)Molecular Medicine Reports (1 paper)
- Partner nations
- CzechiaUnited Kingdom
In The Last Decade
Libor Staněk
10 papers receiving 2.8k citations
Libor Staněk's Hit Papers
Peers
Comparison fields: 5 of 76
- Endocrinology, Diabetes and Metabolism 2.2k
- Pharmacology 315
- Nephrology 119
- Cardiology and Cardiovascular Medicine 299
- Surgery 565
Countries citing papers authored by Libor Staněk
This map shows the geographic impact of Libor Staněk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Libor Staněk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Libor Staněk more than expected).
Fields of papers citing papers by Libor Staněk
This network shows the impact of papers produced by Libor Staněk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Libor Staněk. The network helps show where Libor Staněk may publish in the future.
Co-authors
The 25 scholars most cited alongside Libor Staněk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hit paper breakdown → | 2019 | 2307 |
| 2 | Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Hit paper breakdown → | 2019 | 492 |
| 3 | 2015 | 39 | |
| 4 | 2012 | 10 | |
| 5 | 2014 | 10 | |
| 6 | 2022 | 6 | |
| 7 | 2021 | 4 | |
| 8 | 2017 | 3 | |
| 9 | [Polymerase chain reaction: basic principles and applications in molecular pathology]. | 2013 | 2 |
| 10 | 2016 | 1 | |
| 11 | 2020 | 0 |
About Libor Staněk
Libor Staněk is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism, Obstetrics and Gynecology, Pulmonary and Respiratory Medicine and Genetics, having authored 11 papers that have together received 2.9k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (2 papers), Diabetes Treatment and Management (2 papers), Glioma Diagnosis and Treatment (1 paper), Microtubule and mitosis dynamics (1 paper), Urinary and Genital Oncology Studies (1 paper), Neonatal and Maternal Infections (1 paper), Uterine Myomas and Treatments (1 paper) and Helicobacter pylori-related gastroenterology studies (1 paper). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (2.2k citations), Pharmacology (315 citations), Nephrology (119 citations), Cardiology and Cardiovascular Medicine (299 citations) and Surgery (565 citations). Libor Staněk has collaborated with scholars based in Czechia and United Kingdom. Frequent co-authors include Pavel Dundr, Ján Laco, Kristýna Němejcová, Sarah L. Kenny, W. Glenn McCluggage, Michal Zikan, Petr Škapa, Petra Kleiblová, Lubos B. Petruzelka and Adam Whitley. Their work appears in journals such as The Lancet, The American Journal of Surgical Pathology, Journal of Perinatal Medicine, Medical Science Monitor and Molecular Medicine Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.